medigraphic.com
Patología Revista Latinoamericana

2011, Number 4

<< Back

Patol Rev Latinoam 2011; 49 (4)

Resident forum

Language: Spanish
References: 110
Page: 285-313
PDF size: 590.57 Kb.


Text Extraction

No abstract


REFERENCES

  1. Murphy WM, Grignon DJ, Perlman EJ. Tumors of the kidney, bladder, and related urinary structures. Washington DC: AFIP, Atlas of tumor pathology series 4, 2004;109-149.

  2. Murguía-Pérez M, Hernández-González M, Alcántara-Vázquez A. Carcinoma renal sarcomatoide. Revisión de 7 casos con análisis de inmunohistoquímica. Rev Esp Patol 2010;43(2):73-78.

  3. De Peralta-Venturina M, Moch H, Amin M, Tamboli P, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 2001;25(3):275-284.

  4. Krubasik D, Iyer NG, English WR, Ahmed AA, et al. Absence of p300 induces cellular phenotypic changes characteristic of epithelial to mesenchyme transition. Br J Cancer 2006;94(9):1326-1332.

  5. Kuo MH, Allis CD. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998;20(8):615- 626.

  6. Eguía P. Expression profiles of PCAF and p300 histone acetylases in pediatric astrocytomas. Tesis doctoral en Biología Molecular. Hospital Infantil de México Federico Gómez.

  7. Isharwal S, Miller MC, Marlow C, Makarov DV, et al. p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape. Prostate 2008;68(10):1097-1104.

  8. Información del producto. Anti-p300/CBP monoclonal, SIGMA.

  9. Registro Histopatológico de Neoplasias Malignas en México, 2001.

  10. Terracciano LM, Mhawech P, Suess K, D’Armiento M, et al. Calretinin as a marker for cardiac myxoma. Diagnostic and histogenetic considerations. Am J Clin Pathol 2000;114(5):754- 759.

  11. Li Y, Pan Z, Ji Y, Sheppard M, et al. Herpes simplex virus type 1 infection associated with atrial myxoma. Am J Pathol 2003;163(6):2407-2412.

  12. Burke A, Virmani R. Tumors of the heart and great vessels (Atlas of tumor pathology 3rd series). Washington, DC: Armed Forces Institute of Pathology, 1996;21-44.

  13. Baloch Z, LiVolsi V. Microcarcinoma of the thyroid. Adv Anat Pathol 2006;13:69-75.

  14. LiVolsi V, Albores-Saavedra J, Asa SL, Baloch ZW. Papillary carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. Pathology and genetics of tumours of endocrine organs-World Health Organization Classification of Tumors. Lyon: IARC Press, 2004;57-66.

  15. Frates M, Benson C, Charboneau W. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound Consensus Conference Statement. Radiology 2005;237:794- 800.

  16. Kim D, Kim S, Jung S. Successful sonography-guided fineneedle aspiration biopsy of a 1-millimeter-diameter papillary thyroid microcarcinoma. Am J Neuroradiol 2010;30:1082-1084.

  17. Gamboa-Domínguez A, Lino S, Candanedo F. Tendencias en patología tiroidea en un centro de referencia: prevalencia estable del carcinoma papilar e incremento de la hiperplasia nodular en tiroidectomías. Revista de Investigación Clínica 2011;63:148-154.

  18. Candanedo F, Gamboa-Domínguez A. The many faces of papillary thyroid carcinoma. Advances in selected topics in endocrinology, 2009;257-270.

  19. Hay I, Hutchinson M, González-Losada T. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 2008;144:980-988.

  20. Solares CA, Penalonzo MA, Xu M, Orellana E. Occult papillary thyroid carcinoma in post mortem species: prevalence at autopsy. Am J Otolaryngol 2005;26(2):87-90.

  21. Edge S, Byrd D, Compton C. AJCC Cancer Staging Manual. 7th ed. Nueva York: Springer, 2010.

  22. Yamashita H, Noguchi S, Murakami N. Extracapsular invasion of lymph node metastasis. A good indicator of disease recurrence and poor prognosis in patients with thyroid microcarcinoma. Cancer 1999;86:842-849.

  23. Pelizzo M, Boschin I, Toniato A. Papillary thyroid microcarcinoma (PTMC): prognostic factors, management and outcome in 403 patients. EJSO 2006;32:1144-1148.

  24. Chow S, Law S, Chan J. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer 2003;98:31-39.

  25. Hu A, Clark J, Payne R. Extrathyroidal extension in welldifferentiated thyroid cancer macroscopic vs microscopic as a predictor of outcome. Arch Otolaryngol Head Neck Surg 2007;133:644-649.

  26. Baudin E, Travagli J, Ropers J. Microcarcinoma of the thyroid gland the Gustave-Roussy Institute experience. Cancer 1998;83:553-559.

  27. Roti E, Uberti E, Bondanelli M. Thyroid papillary microcarcinoma: a descriptive and metaanalysis study. Eur J Endocrinol 2008;159:659-673.

  28. Cappelli C, Castellano M, Braga E. Aggressiveness and outcome of papillary thyroid carcinoma (PTC) versus microcarcinoma (PMC): a mono-institutional experience. J Surg Oncol 2007;95:555-560.

  29. Asioli S, Odasso C, Macrì L. Merits of the PMiT (Papillary Microtumor) terminology in the definition of a subset of incidental papillary microcarcinomas of the thyroid. Int J Surg Pathol 2009;17:378-383.

  30. Sugitani I, Hihide Y, Fujimoto M. Symptomatic versus asymptomatic papilar microcarcinoma: a retrospective analy outcome and prognostic factors. Endocrine Journal 1999;461:209-216.

  31. Bernet V. Approach to the patient with incidental papillary microcarcinoma. J Clin Endocrinol Metab 2010;95:3586-3592. 20. Gülben K, Berberoglu U, Çelen O. Incidental papillary microcarcinoma of the thyroid-factors affecting lymph node metastasis. Arch Surg 2008;393:25-29.

  32. Sassolas G, Hafdi-Nejjari Z, Remontet L. Thyroid cancer: is the incidence rise abating? Eur J Endocrinol 2009;160:71-79.

  33. Sakorafas G, Stafyla V, Kolettis T. Microscopic papillary thyroid cancer as an incidental finding in patients treated surgically for presumably bening disease. J Postgrad Med 2007;52:23-26.

  34. Baloch Z, LiVolsi V. Microcarcinoma of the thyroid. Adv Anat Pathol 2006;13:69-75.

  35. LiVolsi V, Albores-Saavedra J, Asa SL, Baloch ZW. Papillary carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. Pathology and genetics of tumours of endocrine organs-World Health Organization Classification of Tumors. Lyon: IARC Press, 2004;57-66.

  36. Frates M, Benson C, Charboneau W. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound Consensus Conference Statement. Radiology 2005;237:794- 800.

  37. Kim D, Kim S, Jung S. Successful sonography-guided fineneedle aspiration biopsy of a 1-millimeter-diameter papillary thyroid microcarcinoma. Am J Neuroradiol 2010;30:1082-1084.

  38. Gamboa-Domínguez A, Lino S, Candanedo F. Tendencias en patología tiroidea en un centro de referencia: prevalencia estable del carcinoma papilar e incremento de la hiperplasia nodular en tiroidectomías. Revista de Investigación Clínica 2011;63:148-154.

  39. Candanedo F, Gamboa-Domínguez A. The many faces of papillary thyroid carcinoma. Advances in selected topics in endocrinology, 2009;257-270.

  40. Hay I, Hutchinson M, González-Losada T. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 2008;144:980-988.

  41. Solares CA, Penalonzo MA, Xu M, Orellana E. Occult papillary thyroid carcinoma in post mortem species: prevalence at autopsy. Am J Otolaryngol 2005;26(2):87-90.

  42. Edge S, Byrd D, Compton C. AJCC Cancer Staging Manual. 7th ed. Nueva York: Springer, 2010.

  43. Yamashita H, Noguchi S, Murakami N. Extracapsular invasion of lymph node metastasis. A good indicator of disease recurrence and poor prognosis in patients with thyroid microcarcinoma. Cancer 1999;86:842-849.

  44. Pelizzo M, Boschin I, Toniato A. Papillary thyroid microcarcinoma (PTMC): prognostic factors, management and outcome in 403 patients. EJSO 2006;32:1144-1148.

  45. Chow S, Law S, Chan J. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer 2003;98:31-39.

  46. Hu A, Clark J, Payne R. Extrathyroidal extension in welldifferentiated thyroid cancer macroscopic vs microscopic as a predictor of outcome. Arch Otolaryngol Head Neck Surg 2007;133:644-649.

  47. Baudin E, Travagli J, Ropers J. Microcarcinoma of the thyroid gland the Gustave-Roussy Institute experience. Cancer 1998;83:553-559.

  48. Roti E, Uberti E, Bondanelli M. Thyroid papillary microcarcinoma: a descriptive and metaanalysis study. Eur J Endocrinol 2008;159:659-673.

  49. Cappelli C, Castellano M, Braga E. Aggressiveness and outcome of papillary thyroid carcinoma (PTC) versus microcarcinoma (PMC): a mono-institutional experience. J Surg Oncol 2007;95:555-560.

  50. Asioli S, Odasso C, Macrì L. Merits of the PMiT (Papillary Microtumor) terminology in the definition of a subset of incidental papillary microcarcinomas of the thyroid. Int J Surg Pathol 2009;17:378-383.

  51. Sugitani I, Hihide Y, Fujimoto M. Symptomatic versus asymptomatic papilar microcarcinoma: a retrospective analy outcome and prognostic factors. Endocrine Journal 1999;461:209-216.

  52. Bernet V. Approach to the patient with incidental papillary microcarcinoma. J Clin Endocrinol Metab 2010;95:3586-3592.

  53. Gülben K, Berberoglu U, Çelen O. Incidental papillary microcarcinoma of the thyroid-factors affecting lymph node metastasis. Arch Surg 2008;393:25-29.

  54. Sassolas G, Hafdi-Nejjari Z, Remontet L. Thyroid cancer: is the incidence rise abating? Eur J Endocrinol 2009;160:71-79.

  55. Sakorafas G, Stafyla V, Kolettis T. Microscopic papillary thyroid cancer as an incidental finding in patients treated surgically for presumably bening disease. J Postgrad Med 2007;52:23-26.

  56. Ferlay J. Cancer incidence and a mortality worldwide (IARC Cancer Bases No.5). Lyon 2001.

  57. Registro histopatológico de neoplasias en México, DGE/SSA, 1999.

  58. Ugalde-Puyol J, Pérez-Rovalino M, Palta A, Patiño M. Cáncer gástrico: factores pronósticos moleculares mediante tissue microarray de bajo costo. X Congreso Virtual Hispanoamericano de Anatomía Patológica, Ecuador, 2009.

  59. Tuefferd M, Couturier J, Penault-Llorca F, et al. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS ONE 2007;2:1138.

  60. Koeppen HKW, Wright BD, Burt AD, et al. Overexpression of HER2/neu in solid tumors: an inmunohistochemical survey. Histopathology 2001;38:96-104.

  61. Paradelo M, Gay R, Grupe V, DI Tada C, Landini P. Sobreexpresión del marcador HER2 en carcinoma gástrico. Curso internacional de la Sociedad Argentina de Patología, 2009.

  62. Tanner M, Hollmén M, Junttila TT, et al. Amplification of HER2 in gastric carcinoma: association with topoisomerasa IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273-278.

  63. Hoffman M, Stoss O, Shi D, Büttner R, et al. Assessment of HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805.

  64. Kumar, Vinay, et al. Robbins and Cotran. Pathologic basis of disease. 7th ed. Barcelona: Elsevier, 2009;826-830.

  65. Guzmán-Delgado N, Cruz-Vega E, Garza-Garza R, et al. Expresión de la oncoproteína HER-2/neu en cáncer gástrico. Revista salud pública y nutrición 2004;4:10.

  66. Roche. Comunicado de prensa: Herceptin aprobado en la UE contra el cáncer de estómago HER2-positivo avanzado, Basilea, enero 2010.

  67. Moore KL, Dalley AF. Anatomía con orientación clínica. 4ª ed. Barcelona: Editorial Médica Panamericana, 2002:230-235.

  68. Gennesser F. “Histología”. 3ª ed., Buenos Aires: Editorial Médica Panamericana, 2001;488-498.

  69. Palacios J, Andreu X, et al. Recomendación para la determinación de HER-2 en cáncer de mama, consenso nacional de la Sociedad Española de Anatomía Patológica (SEAP) y de la Sociedad Española de Oncología Médica (SEOM). Rev Esp Patol 42(1):3-16.

  70. Yang D, Hendifar A, Lenz C, et al. Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. J Gastrointest Oncol 2011;2:77-84.

  71. Dicken BJ, Bigam DL, Cass C, Mackey JR, et al. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005;241:27-39.

  72. Rüschoff J, Dietel M, Baretton G, Arbogast S, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010;457:299-307.

  73. Shi-Yan Y, Ying H, Jian-Gao F, Guo-Quan T, et al. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol 2011;17(11):1501-1506.

  74. Slamon DJ, Clark GM, Wong SG, Levin WJ, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177- 182.

  75. Lee JH, Ryu KW, Lee JR, Kim CG, et al. Decisions for extent of gastric surgery in gastric cancer patients: younger patients require more attention than the elderly. J Surg Oncol 2007;95:485-490.

  76. Tso PL, Bringaze WL 3rd, Daauterive AH, Correa P, Cohn I Jr. Gastric carcinoma in the young. Cancer 1987;59:1362-1365.

  77. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19:1523-1529.

  78. Park DI, Yun JW, Park JH, Oh SJ, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006;51:1371-1379.

  79. Sanz-Anquela JM, Ruiz-Liso JM, Rodriguez-Manzanilla L, Alfaro-Torres J, et al. Importancia de la clasificación de Luren del cáncer gástrico. Revisión de una serie de 295 casos. Patología 1989;22:156-161.

  80. Albarello L, Pecciarini L, Doglioni C, et al. HER2 Testing in Gastric Cancer. Adv Anat Pathol 2011;18(1):53-59.

  81. Berne R, Levy MN. Fisiología. 2a ed. España: Harcourt Brace, 1998.

  82. Gartner L, Hiatt JL. Texto atlas de histología. 2ª ed. Estados Unidos: McGraw-Hill, 2002.

  83. Mills SE. Histology for pathologists. 3ª ed. Filadelfia: Lippincott Williams and Wilkins, 2007.

  84. Fish JE, Srivastava D. MicroRNAs: Opening a new win in angiogenesis research. Sci Signal 2009.

  85. Hernando Ulloa, Ulloa Domínguez. Angiogénesis en patología arterial periférica. Med 2005;13(1):29-36.

  86. Remuzzi G, Ruggenenti P, Bertani T. Thrombotic microangiopathies. In: Tisher CC, Brenner BM, editors. Renal pathology. With clinical and functional correlations. Philadelphia: JB Lippincott Company, 1994;1154-1184.

  87. Zhan Z, et al. MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS lett. 2009;583(12):2009-2014. Epub 2009 May 19.

  88. Tsai HM. The molecular Biology of thrombotic microangiopathy. Kidney Int 2006;70(1): 16-23.

  89. Fogo AB, Kashgarian M. Diagnostic atlas of renal pathology. Estados Unidos: Elsevier Saunders, 2005

  90. Urbich C, Kuehbacher A. Role of microRNAs en enfermedades vasculares, inflamación y angiogénesis. Cardiovascular Research 2008;79:581-588.

  91. Jorge DL, et al. Carcinoma mamario con inmunofenotipo similar al de las células basales. Estudio morfológico y perfil de expresión inmunohistoquímico de 54 casos triple negativos. Patología Rev Latinoam 2008;46(4):303-308.

  92. Korsching E, et al. Basal carcinoma of the breast revisited: and old entity with new interpretations. J Clin Pathol 2008;61:553- 560.

  93. Nielsen T, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-5374.

  94. Dabbs DJ. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Modern Pathology 2006;19:1506-1511.

  95. Lerma E, et. al. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). Modern Pathology 2007;20:1200-1207.

  96. Kim MJ, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 2006;37(9):1217-1226.

  97. Laakso M, et al. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol 2005;18(10):1321-1328.

  98. Livasy CA, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19(2):264-271.

  99. Fulford LG, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006;49(1):22-34.

  100. Jumppanen M, et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res 2007;9(1):R1.

  101. Carey LA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295(21):2492- 2502.

  102. Olaya Guzmán EJ. Cáncer de mama triple negativo, estado actual. Rev Esp Méd Quir 2010;15:228-236.

  103. Gnepp Douglas R. Diagnostic surgical pathology of the head and neck. 2nd ed. China: Saunders Elsevier, 2009;352-353.

  104. Cardesa A, et al. Pathology of the head and neck. 2nd ed. Germany: Springer, 2006;3-4.

  105. Stocker JT, et al. Pediatric pathologic. 2nd ed. Toronto: Lippincott Williams & Wilkins, 2002;vol 1:100-105.

  106. Sebire NJ, et al. Diagnostic pediatric surgical pathology. 7a ed. New York: Churchill Livingstone, 2010;130-133.

  107. Mills SE, et al. Sternberg’s diagnostic surgical pathology. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2004;1:110-111.

  108. Connor DH, et al. Pathology of infectious disease. Hong Kong, Appleton & Lange, 1997;1:199-208.

  109. Ball E. Virus papiloma humano. Biología molecular, genética y mecanismo oncogénico parte 1. Dermatologia Venezolana 1998;36(4).

  110. Girishwar S, et al. Correlation of histology, human papillomavirus, and viral load in laryngeal papillomas of childhood. Diagn Mol Pathol 2005;14(4):230-236.




2020     |     www.medigraphic.com